Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine
Altamira Therapeutics (OTCQB:CYTOF) has received allowance for its Japanese patent application covering intranasal betahistine formulations and methods of use. The patent specifically covers the company's AM-125 nasal spray program, which is designed to treat dizziness.
The Japan Patent Office Board of Appeals' decision strengthens Altamira's intellectual property portfolio, which now includes patent coverage for AM-125 in more than 50 countries, including major markets in North America and Europe. The company plans to commercialize AM-125 through strategic partnerships to address the needs of patients suffering from dizziness.
Altamira Therapeutics (OTCQB:CYTOF) ha ottenuto l'approvazione per la sua domanda di brevetto giapponese riguardante formulazioni intranasali di betahistina e relativi metodi d'uso. Il brevetto copre specificamente il programma spray nasale AM-125 dell'azienda, progettato per trattare la vertigine.
La decisione del Consiglio d'Appello dell'Ufficio Brevetti Giapponese rafforza il portafoglio di proprietà intellettuale di Altamira, che ora include la copertura brevettuale per AM-125 in oltre 50 paesi, compresi i principali mercati del Nord America e dell'Europa. L'azienda prevede di commercializzare AM-125 attraverso partnership strategiche per rispondere alle esigenze dei pazienti affetti da vertigine.
Altamira Therapeutics (OTCQB:CYTOF) ha recibido la aprobación de su solicitud de patente en Japón que cubre formulaciones intranasales de betahistina y métodos de uso. La patente cubre específicamente el programa de spray nasal AM-125 de la compañía, diseñado para tratar el mareo.
La decisión de la Junta de Apelaciones de la Oficina de Patentes de Japón fortalece la cartera de propiedad intelectual de Altamira, que ahora incluye protección de patente para AM-125 en más de 50 países, incluyendo mercados clave en Norteamérica y Europa. La empresa planea comercializar AM-125 mediante alianzas estratégicas para atender las necesidades de los pacientes que sufren de mareo.
Altamira Therapeutics (OTCQB:CYTOF)는 비강 내 베타히스틴 제형 및 사용 방법을 포함하는 일본 특허 출원이 승인되었습니다. 이 특허는 특히 어지럼증 치료를 위해 설계된 회사의 AM-125 비강 스프레이 프로그램을 포함합니다.
일본 특허청 항소위원회의 결정은 북미 및 유럽의 주요 시장을 포함한 50개국 이상에서 AM-125에 대한 특허권을 보유한 Altamira의 지적 재산권 포트폴리오를 강화합니다. 회사는 어지럼증 환자의 요구를 충족하기 위해 전략적 파트너십을 통해 AM-125를 상용화할 계획입니다.
Altamira Therapeutics (OTCQB:CYTOF) a obtenu l'autorisation pour sa demande de brevet japonaise couvrant des formulations intranasales de bétahistine et leurs modes d'utilisation. Le brevet couvre spécifiquement le programme de spray nasal AM-125 de la société, conçu pour traiter les vertiges.
La décision du Conseil d'appel de l'Office des brevets du Japon renforce le portefeuille de propriété intellectuelle d'Altamira, qui comprend désormais une protection par brevet pour AM-125 dans plus de 50 pays, y compris les principaux marchés en Amérique du Nord et en Europe. La société prévoit de commercialiser AM-125 via des partenariats stratégiques afin de répondre aux besoins des patients souffrant de vertiges.
Altamira Therapeutics (OTCQB:CYTOF) hat die Zulassung für seine japanische Patentanmeldung erhalten, die intranasale Betahistin-Formulierungen und deren Anwendungsmethoden abdeckt. Das Patent umfasst speziell das AM-125 Nasenspray-Programm des Unternehmens, das zur Behandlung von Schwindel entwickelt wurde.
Die Entscheidung des Berufungsausschusses des Japanischen Patentamts stärkt Altamiras geistiges Eigentum, das nun Patentschutz für AM-125 in mehr als 50 Ländern umfasst, darunter wichtige Märkte in Nordamerika und Europa. Das Unternehmen plant, AM-125 durch strategische Partnerschaften zu vermarkten, um den Bedürfnissen von Patienten mit Schwindel gerecht zu werden.
- Patent coverage secured in Japan, one of the largest pharmaceutical markets globally
- Extensive patent protection in over 50 countries including key North American and European markets
- Strategic partnership opportunities for commercialization
- None.
HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the Japan Patent Office Board of Appeals determined that the Company's patent application on the composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery is allowable. The application covers the Company's intranasal betahistine program (AM-125).
"We are very pleased to obtain patent coverage on our AM-125 nasal spray program also in Japan, one of the largest pharma markets world-wide," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. "To date, we have secured patent coverage for AM-125 in more than 50 countries worldwide, including key markets in North America and Europe. Through collaboration with appropriate partners, we intend to bring AM-125 to the many patients worldwide who are suffering from dizziness."
About Betahistine
Betahistine, a small molecule structural analog of histamine, acts as an agonist at the H1 histamine receptor and as an antagonist at the H3 histamine receptor. Unlike histamine, it crosses the blood-brain-barrier. Betahistine is known to increase the release of histamine, acetylcholine, dopamine and norepinephrine in the brain. It increases cochlear, vestibular and cerebral blood flow and facilitates vestibular compensation and inhibits neuronal firing in the vestibular nuclei. Betahistine for oral administration is approved in about 115 countries (with the U.S. being a notable exception) for the treatment of vertigo and Meniere's disease. Despite its good safety profile, the clinical utility of orally administered Betahistine is limited due to poor bioavailability.
About AM-125
AM-125 is an intranasal formulation of betahistine. Because of its ability to circumvent first-pass-metabolism, AM-125 has been shown to have 5-to-29 times higher bioavailability than orally administered betahistine. Altamira Therapeutics has been developing AM-125 for the treatment of acute vestibular syndrome (vertigo). With its incidence and prevalence increasing with age, vestibular dysfunction affects more than one third of the U.S. population 40 years of age and older.
About Altamira Therapeutics
Altamira Therapeutics is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The versatile delivery platform is suited for different RNA modalities, including siRNA, mRNA and circRNA, and made available to pharma or biotech companies through out-licensing. The Company has two proprietary flagship programs based on xPhore and siRNA payloads: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. In addition, Altamira holds a
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include but are not limited to the clinical utility of Altamira's product candidates, the timing or likelihood of regulatory filings and approvals, Altamira's intellectual property position and Altamira's financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira's Annual Report on Form 20-F for the year ended December 31, 2024, and in Altamira's other filings with the Securities Exchange Commission ("SEC"), which are available free of charge on the SEC's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
SOURCE: Altamira Therapeutics Ltd.
View the original press release on ACCESS Newswire
FAQ
What patent did Altamira Therapeutics (CYTOF) receive in Japan?
How many countries now have patent coverage for Altamira's AM-125 program?
What is the purpose of Altamira's AM-125 nasal spray?
What are Altamira's commercialization plans for AM-125?
